Literature DB >> 26948256

Experiences of Being Heterozygous for Fabry Disease: a Qualitative Study.

Charlotte von der Lippe1, Jan C Frich2, Anna Harris3, Kari Nyheim Solbrække2.   

Abstract

Little is known about the experiences of women with Fabry disease. The aim of this study was to explore women's experiences of being heterozygous for Fabry disease. We used an explorative qualitative study design and selected ten Norwegian women who were known heterozygous for Fabry disease to participate. We conducted in-depth semi-structured interviews and analyzed the interviews using inductive thematic analysis. We found that learning about one's heterozygous status may be devastating for some. However, for most of the participants, heterozygous status, as well as doctors' acceptance of symptoms in women heterozygous for Fabry disease, provided an explanation and relief. Although many women did not consider themselves ill, they wished to be acknowledged as more than "just carriers." The participants were grateful for enzyme replacement therapy, although it had its burdens regarding time, planning, and absences from school or work. Women with Fabry disease felt that the lack of knowledge among healthcare professionals about Fabry disease was frustrating and worrisome. These findings suggest that healthcare professionals should acknowledge the different ways women react to their diagnosis, and be aware of the personal costs of receiving treatment.

Entities:  

Keywords:  Experiences; Fabry disease; Genetic counseling; Heterozygous; Psychosocial; X-linked

Mesh:

Year:  2016        PMID: 26948256     DOI: 10.1007/s10897-016-9941-1

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  30 in total

1.  Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria.

Authors:  Thomas P Mechtler; Susanne Stary; Thomas F Metz; Víctor R De Jesús; Susanne Greber-Platzer; Arnold Pollak; Kurt R Herkner; Berthold Streubel; David C Kasper
Journal:  Lancet       Date:  2011-11-29       Impact factor: 79.321

2.  The psychosocial impact of epidermolysis bullosa.

Authors:  Emma Dures; Marianne Morris; Kate Gleeson; Nichola Rumsey
Journal:  Qual Health Res       Date:  2011-02-22

3.  Identity and adherence in a diabetes patient: transformations in psychotherapy.

Authors:  Barbara Tilden; Denise Charman; Jenny Sharples; Jackie Fosbury
Journal:  Qual Health Res       Date:  2005-03

4.  Psychosocial impact of an X-linked hereditary disease: a study of Alport syndrome patients and family members.

Authors:  H Pajari; J Sinkkonen
Journal:  Child Care Health Dev       Date:  2000-05       Impact factor: 2.508

5.  Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

Authors:  R Schiffmann; J B Kopp; H A Austin; S Sabnis; D F Moore; T Weibel; J E Balow; R O Brady
Journal:  JAMA       Date:  2001-06-06       Impact factor: 56.272

6.  Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study.

Authors:  Takahito Inoue; Kiyoko Hattori; Kenji Ihara; Atsushi Ishii; Kimitoshi Nakamura; Shinichi Hirose
Journal:  J Hum Genet       Date:  2013-05-16       Impact factor: 3.172

7.  Loss of self: a fundamental form of suffering in the chronically ill.

Authors:  K Charmaz
Journal:  Sociol Health Illn       Date:  1983-07

8.  Comparison of health-related quality of life between heterozygous women with Fabry disease, a healthy control population, and patients with other chronic disease.

Authors:  Natalie Jansen Street; Michael S Yi; Laurie A Bailey; Robert J Hopkin
Journal:  Genet Med       Date:  2006-06       Impact factor: 8.822

Review 9.  Fabry disease.

Authors:  Dominique P Germain
Journal:  Orphanet J Rare Dis       Date:  2010-11-22       Impact factor: 4.123

10.  Increased genetic counseling support improves communication of genetic information in families.

Authors:  Laura E Forrest; Jo Burke; Sonya Bacic; David J Amor
Journal:  Genet Med       Date:  2008-03       Impact factor: 8.822

View more
  7 in total

1.  "It was a lot Tougher than I Thought It would be". A Qualitative Study on the Changing Nature of Being a Hemophilia Carrier.

Authors:  Charlotte von der Lippe; Jan C Frich; Anna Harris; Kari Nyheim Solbrække
Journal:  J Genet Couns       Date:  2017-05-26       Impact factor: 2.537

Review 2.  The Psychosocial Impact of Carrying a Debated Variant in the GLA Gene.

Authors:  Sarah Macklin; Dawn Laney; Emily Lisi; Andrea Atherton; Elizabeth Smith
Journal:  J Genet Couns       Date:  2017-08-10       Impact factor: 2.537

Review 3.  Living with a rare disorder: a systematic review of the qualitative literature.

Authors:  Charlotte von der Lippe; Plata S Diesen; Kristin B Feragen
Journal:  Mol Genet Genomic Med       Date:  2017-07-23       Impact factor: 2.183

4.  Depressive symptoms in Fabry disease: the importance of coping, subjective health perception and pain.

Authors:  Simon Körver; Gert J Geurtsen; Carla E M Hollak; Ivo N van Schaik; Maria G F Longo; Marjana R Lima; Leonardo Vedolin; Marcel G W Dijkgraaf; Mirjam Langeveld
Journal:  Orphanet J Rare Dis       Date:  2020-01-28       Impact factor: 4.123

5.  Interventions for and experiences of shared decision-making underpinning reproductive health, family planning options and pregnancy for women with or at high risk of kidney disease: a systematic review and qualitative framework synthesis.

Authors:  Leah Mc Laughlin; Barbara Neukirchinger; Jane Noyes
Journal:  BMJ Open       Date:  2022-08-08       Impact factor: 3.006

6.  A survey on the patient journey in Fabry disease in Japan.

Authors:  Mina Tsurumi; Asuka Ozaki; Yoshikatsu Eto
Journal:  Mol Genet Metab Rep       Date:  2022-08-17

7.  Cognitive functioning and depressive symptoms in Fabry disease: A follow-up study.

Authors:  Simon Körver; Gert J Geurtsen; Carla E M Hollak; Ivo N van Schaik; Maria G F Longo; Marjana R Lima; Marcel G W Dijkgraaf; Mirjam Langeveld
Journal:  J Inherit Metab Dis       Date:  2020-06-25       Impact factor: 4.982

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.